Skip to content
2000
Volume 15, Issue 6
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Systemic lupus erythematosus is more than a heterogeneous autoimmune disease. It is in fact a syndrome of many different clinical genotypes and phenotypes. This review covers the most recently studied monoclonal antibodies and those currently being investigated. The key trials are summarized, including those for biologics on the market for two decades and those just approved for lupus less than two years ago. The focus will be on the following four: Rituximab, Abatacept, Belimumab, and Epratuzumab. It is a challenge to design the perfect trial and study patients with this disease as each has his or her own unique manifestations, biological markers, and underlying genetic background. However, as our understanding of the immune mechanisms involved in lupus increases; novel therapies will emerge that can be utilized for appropriately selected patients.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/1389201015666140804162053
2014-06-01
2025-07-15
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/1389201015666140804162053
Loading

  • Article Type:
    Research Article
Keyword(s): Antibodies; biologics; lupus; monoclonal antibody; SLE; systemic lupus erythematosus; treatment
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test